Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness - PubMed (original) (raw)
Comparative Study
. 2008 Jan;103(1):146-54.
doi: 10.1111/j.1360-0443.2007.02083.x. Epub 2007 Nov 19.
Affiliations
- PMID: 18028247
- DOI: 10.1111/j.1360-0443.2007.02083.x
Comparative Study
Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness
John A Stapleton et al. Addiction. 2008 Jan.
Abstract
Aims: To compare the effectiveness of varenicline with nicotine replacement for smoking cessation and to evaluate the safety and effectiveness of varenicline in people with mental illness.
Design: Evaluation of consecutive routine cases before and after the introduction of varenicline.
Setting: National Health Service (NHS) tobacco dependence clinic in London, UK.
Participants: A total of 412 cases receiving routine care.
Intervention: Seven group support sessions over 6 weeks with either nicotine replacement therapy (NRT) (n = 204) or varenicline (n = 208).
Measurements: Verified abstinence 4 weeks after quit day, severity of withdrawal symptoms, incidence and severity of adverse drug symptoms, cost per patient treated and cost per successful short-term quitter.
Findings: Short-term cessation rates were higher with varenicline than NRT (odds ratio = 1.70, 95% confidence interval = 1.09-2.67). Varenicline was equally effective in those with and without mental illness. Craving to smoke, but not adverse mood, was less severe with varenicline than NRT. The cost per quitter was similar for varenicline and NRT. There was a higher incidence of adverse drug symptoms among those taking varenicline, but these were tolerated by most smokers. There was no evidence that varenicline exacerbated mental illness.
Conclusions: In this setting and with group support varenicline appears to improve success rates over those achieved with NRT, and is equally effective and safe in those with and without a mental illness.
Similar articles
- Combination treatment with varenicline and nicotine replacement therapy.
Ebbert JO, Burke MV, Hays JT, Hurt RD. Ebbert JO, et al. Nicotine Tob Res. 2009 May;11(5):572-6. doi: 10.1093/ntr/ntp042. Epub 2009 Apr 7. Nicotine Tob Res. 2009. PMID: 19351781 - Characteristics and abstinence outcomes among tobacco quitline enrollees using varenicline or nicotine replacement therapy.
Biazzo LL, Froshaug DB, Harwell TS, Beck HN, Haugland C, Campbell SL, Helgerson SD. Biazzo LL, et al. Nicotine Tob Res. 2010 Jun;12(6):567-73. doi: 10.1093/ntr/ntq045. Epub 2010 Apr 8. Nicotine Tob Res. 2010. PMID: 20378640 - Flexible and extended dosing of nicotine replacement therapy or varenicline in comparison to fixed dose nicotine replacement therapy for smoking cessation: rationale, methods and participant characteristics of the FLEX trial.
Tulloch H, Pipe A, Els C, Aitken D, Clyde M, Corran B, Reid RD. Tulloch H, et al. Contemp Clin Trials. 2014 Jul;38(2):304-13. doi: 10.1016/j.cct.2014.05.011. Epub 2014 May 23. Contemp Clin Trials. 2014. PMID: 24861558 Clinical Trial. - The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.
Foulds J. Foulds J. Int J Clin Pract. 2006 May;60(5):571-6. doi: 10.1111/j.1368-5031.2006.00955.x. Int J Clin Pract. 2006. PMID: 16700857 Review. - Efficacy and safety of varenicline for smoking cessation.
Hays JT, Ebbert JO, Sood A. Hays JT, et al. Am J Med. 2008 Apr;121(4 Suppl 1):S32-42. doi: 10.1016/j.amjmed.2008.01.017. Am J Med. 2008. PMID: 18342165 Review.
Cited by
- A virtual reality craving study in tobacco addiction: The role of non-pharmacological support in tobacco detox therapy.
Zamboni L, Campagnari S, Giordano R, Fusina F, Carli S, Congiu A, Barbon I, Melchiori S, Casari R, Tedeschi E, Vesentin R, Verlato G, Infante MV, Lugoboni F. Zamboni L, et al. Front Psychiatry. 2022 Oct 13;13:940100. doi: 10.3389/fpsyt.2022.940100. eCollection 2022. Front Psychiatry. 2022. PMID: 36311510 Free PMC article. - Outcomes from a computer-assisted intervention simultaneously targeting cannabis and tobacco use.
Lee DC, Budney AJ, Brunette MF, Hughes JR, Etter JF, Stanger C. Lee DC, et al. Drug Alcohol Depend. 2015 Oct 1;155:134-40. doi: 10.1016/j.drugalcdep.2015.08.001. Epub 2015 Aug 10. Drug Alcohol Depend. 2015. PMID: 26307942 Free PMC article. Clinical Trial. - ADHD symptoms impact smoking outcomes and withdrawal in response to Varenicline treatment for smoking cessation.
Bidwell LC, Karoly HC, Hutchison KE, Bryan AD. Bidwell LC, et al. Drug Alcohol Depend. 2017 Oct 1;179:18-24. doi: 10.1016/j.drugalcdep.2017.06.020. Epub 2017 Jul 18. Drug Alcohol Depend. 2017. PMID: 28738266 Free PMC article. - Biomarkers to optimize the treatment of nicotine dependence.
Schnoll RA, Leone FT. Schnoll RA, et al. Biomark Med. 2011 Dec;5(6):745-61. doi: 10.2217/bmm.11.91. Biomark Med. 2011. PMID: 22103610 Free PMC article. Review. - A preliminary benefit-risk assessment of varenicline in smoking cessation.
Cahill K, Stead L, Lancaster T. Cahill K, et al. Drug Saf. 2009;32(2):119-35. doi: 10.2165/00002018-200932020-00005. Drug Saf. 2009. PMID: 19236119 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical